iPhone Medical Apps, part 2

Part one was a blog post here.  That page includes comments and suggestions from readers.

National Library of Medicine Launches Mobile MedlinePlus to Meet the Health Information Needs of an On-the-Go Public

Wondering what the side effects are for your new prescription? Go to Mobile MedlinePlus (http://m.medlineplus.gov) while you’re waiting for the pharmacist to fill your order!

Or, instantly look up the symptoms of H1N1 flu if you’re at the supermarket and your child’s school calls you to tell you he doesn’t feel well.

The National Library of Medicine’s Mobile Medline Plus builds on the NLM’s MedlinePlus Internet service, which provides authoritative consumer health information to over 10 million visitors per month. These visitors access MedlinePlus (http://medlineplus.gov) from throughout the United States as well many other countries, and use desktop computers, laptops and even mobile devices to get there.

The mobile Internet audience is large and growing fast, almost doubling from February 2007 to February 2009. Some experts predict that within the next five years, more people will connect to the Internet via mobile devices than via desktop or laptop computers. People use their mobile devices to accomplish a variety of tasks, including finding health information. With this in mind, NLM developed the mobile version of MedlinePlus to bring high-quality health information to users on the go.

“We know that a huge number of people are seeking good health information on the Web, noted NLM Director Dr. Donald A.B. Lindberg. What better way to reach out to them than by offering this new mobile service, which delivers trustworthy, consumer-friendly information instantly, anywhere?”

Mobile MedlinePlus is available in English and Spanish (http://m.medlineplus.gov/spanish) and includes a subset of content from the full Web site. It includes summaries for over 800 diseases, wellness topics, the latest health news, an illustrated medical encyclopedia, and information on prescription and over-the-counter medications.

For instance, you could visit the “Talking With Your Doctor” page on Mobile MedlinePlus to learn how to get the most out of your doctor’s visit.

Mobile MedlinePlus can also help you when you’re trying to choose an over-the-counter cold medicine at the drug store.

And if you’re traveling abroad, you can use Mobile MedlinePlus to learn about safe drinking water.

Mobile MedlinePlus puts reliable health information at your fingertips.

*High resolution screen shot of Mobile MedlinePlus available upon request.

The National Library of Medicine is part of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. It is the nation’s largest medical library.

The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

From http://www.nih.gov/news/health/jan2010/nlm-22.htm?utm_source=twitterfeed&utm_medium=twitter

Elvis, steriod-induced Cushing’s

This is an interesting article…

From http://www.dailymail.co.uk/news/article-1243063/They-called-The-Man-Who-Killed-Elvis-Now-stars-doctor-finally-reveals-true-madness-Kings-final-days.html

..The doctor’s first thought was that Elvis had had a seizure and he injected him with a stimulant to improve his breathing. Then he and Elvis’s manager dragged him into the ensuite bathroom and managed to get him into the bath, which they filled with cold water. Soon they were dressing him in his stage clothes.

Incredibly Elvis managed to perform that night, leaving Dr Nick determined to find out what had caused the handsome man he first met to degenerate into the bloated figure he had become.

Elvis himself refused to give him any clues. Finally, one of his problems was revealed – he and Priscilla were getting divorced. Three days after the final decree was issued in California, the singer, in worse condition than he had ever been, chartered a plane back to Graceland and called for Dr Nick.

This time the doctor arrived to find his patient’s face puffy, pink and almost transparent, and his stomach distended. He suspected either an allergic reaction or heart failure, especially since heart disease ran in the family.

Hospital tests established that Elvis had hepatitis, an enlarged liver ( possibly from painkillers) and Cushing’s syndrome. The last was a hormonal disease that caused bloating, and was down to the many steroids he had been taking to combat the asthma that ran in the family and his ongoing colon problems.

When Dr Nick asked him why he was also covered in bruises, Elvis tried to tell him the marks were from acupuncture needles. Finally he confessed that a couple of Beverly Hills physicians had prescribed the narcotic Demerol to cure back and neck pain, and Novocaine to reduce the pain at the injection sites…

What do you think?

New! Cushie Tools

I saw this on another site and I stayed up all night making one for Cushies because I thought it was so cool.

This is a toolbar you can install on any browser and it will link to what I think are the most important parts of the Cushing’s websites. If you have other ideas, please let me know.

Right now, this contains (from left to right)

  1. The Cushie ribbon icon which takes you to the home page of the newer cushie.info site. Click on the little down arrow to the right of the ribbon and another whole menu appears!


  2. Next to that is a Google search box.
  3. An icon for the 911 Adrenal Crisis! page
  4. A link to the Cushie Reads book recommendations page on amazon.com
  5. The Cushie Calendar
  6. All the bios, arranged by diagnosis type
  7. Add (or update) your bio
  8. Our locations around the world
  9. The message boards and chatroom
  10. Helpful Doctors list
  11. Add (or update) your Helpful Doctor
  12. The Support page where people can make donations to help keep all these websites going.
  13. A little scrolling message area for Cushing’s news.
  14. Cushing’s blogs. I’m still working on this – and I’m not sure how many I can add but for the moment, this blog is included as well as Cushie Bloggers and survive the journey

    When any of these update, the icon changes to show that there are new posts.

    This area now includes NIH Clinical trials for Cushing’s, pituitary and adrenal. Be the first to know when new trials are listed.

  15. The Cushings Help Organization cause on Facebook
  16. Links to Staticnrg and Cushings on Twitter. Again, more can be added. If you talk mostly about Cushing’s on Twitter, please let me know.
  17. The new CushieWiki. BTW, please feel free to sign up and become a contributor/editor.
  18. A radio button – you can play the Cushing’s podcasts right from this toolbar. You can also add stations that you’d like to listen to.
  19. You can also add other modules like games, weather, email, hundreds of different things.

Download this toolbar or see a sample.

About privacy:

cushie tools is committed to maintaining the following privacy practices:

  1. No Spyware Policy – the toolbar does not collect or transmits Identifiable information and does not monitor personal toolbar usage.
    The toolbar sends unidentifiable and non-personal statistical data to enable quality assurance and improve support processes. Such non-personal data includes unidentifiable usage of toolbar components and queries. You can opt not to send such statistical data at any time from your toolbar Options dialog box.
  2. No Adware Policy : exposure to unwanted advertisements is not required in order to use the toolbar. The toolbar does not launch pop-up or pop-under advertisement windows or any other type of obtrusive ads.
  3. Unobtrusive: The toolbar does not enable other applications to access data stored on your computer’s hard drive or in your online accounts. The toolbar does not modify pages you visit or modify your search experience. You may voluntarily opt to receive Publisher notifications (such as Community Alerts) or use other advanced functionalities offered by cushie tools.
  4. Easy uninstall : you can easily uninstall the toolbar at any time using the toolbar’s standard uninstall package (Add/Remove Programs in Windows, Add-on Removal in Firefox, etc.).
  5. Easy deactivation: you can easily deactivate your toolbar at any time by clicking the “View” menu in your browser and deselecting the name of your community toolbar.
  6. Full control : you have full control over your toolbar and you can add/remove toolbar components at any time using your toolbar’s Options dialog box.
  7. Report – cushie tools is committed to ensuring your Privacy and safety while using your community toolbar. If you have a reason to believe that your rights have been infringed upon, please email privacy@conduit.com to contact the owners of Platform that was used by cushie tools to create your community toolbar, and your application will be handled at the earliest convenience.

Finally, I would like to add that installing this toolbar is possibly a way for the sites to make a little money although the hosting site doesn’t disclose how much they give back and how many people have to do how much searching to make any kind of profit.

The theory is that Google pays the host company, Conduit, like it does for Google ads – I’ve seen them on other sites but have never used them because I want to try to keep the sites ad free and non-tacky. Then, depending on the number of people who have installed this toolbar, and how much they use it, a percentage of that money is supposed to come back to Cushing’s Help.

I have no expectations of making any money, though. I just thought that it looked like an interesting new way for people to find things easily on the websites, listen to podcasts, and get the latest news.

Please note – after installation there’s a little popup window that says you might get alerts. I promise I won’t send those out unless it’s something serious like the boards are back up after a day of being down.

Thanks for reading! I hope you’ll give this a try.

Participating in Life

I think that this is so important, especially with our health.  Had I not been an active participant and followed several doctors’ advice 25 years ago, I’d most likely not been here to write this.

I see this all the time, though.  Whatever the doctor says is true.  People will say that the doctor gave me this or that med but they don’t know what it is for.

I just don’t get how people can take meds and not have a clue what they are, how they work, how they might interact with other drugs they may be taking.  But it happens because people blindly follow whatever a doctor may give them.

Participation is so important – you have to know how YOU’RE feeling, what YOUR symptom are.  Do your own research.  Your doctor doesn’t know what it feels like to live in your body no matter how much you try to tell him/her.

Ultimately, you are the one who cares most about yourself and the only one who can make a difference through your research, thoughts and actions.

Just because a doctor gives you something, you don’t have to take it.  24 years ago a locally well-known neurologist “gave me” Xanax. Since he couldn’t see my tumor with his Magnetic Resonance Imaging (MRI) machine there was “no possibility” that it existed.  Had I followed his advice, taken the Xanax and stopped pursuing a Cushing’s diagnosis I would most have likely died by now.

The doctor was going by the odds.  The odds were that I really didn’t have a pituitary tumor.  But I’m not a statistic and neither are you.  Follow your instincts and take care of YOU.  This is the only life you’ll ever have.

The most healing thing we can do for ourselves is to participate in the process of our lives as fully as we can-even when the unexpected and the fearful happen.

~Today’s Page-a-Day calendar

What do YOU do to keep participating in your health care and daily life?

Four Anticipated Milestones for 2010

Maybe, finally, things are looking up for Cushies?  There have been so many ideas, trials, false starts over the years.

When I was at NIH in 1987, I had tests that they thought would help diagnose Cushing’s earlier.  No one has those tests anymore so I guess they didn’t do the trick.  But they have been trying for at least 23 years to find something to help people get diagnosed a little earlier.

There has been improvement in the drug area, too. Back then, no growth hormone, no  ketoconazole to take to lower cortisol, although that was used as a testing agent.

Being diagnosed with Cushing’s may still seem to take forever but there have been improvements over these years, slow but sure.

One of our members, Lori, sent this information along about some hopeful news for 2010.

Corcept Therapeutics Announces Four Anticipated Milestones for 2010

Completion of Enrollment of CORLUX Pivotal Phase 3 Trial for Cushing’s Syndrome in 1Q 2010; Announcement of Results From the CORLUX Phase 3 Trial for Cushing’s Syndrome in 3Q 2010; Submission of CORLUX New Drug Application (NDA) for Cushing’s Syndrome in 4Q 2010; Initiation of Phase 1 for Selective GR-II Antagonist — CORT 108297 — in 1Q 2010

MENLO PARK, CA–(Marketwire – 01/05/10) – Corcept Therapeutics Incorporated (NASDAQ:CORT – News), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, announces its anticipated milestones for 2010.

“These four milestones should mark a transformational year for the company,” said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept. “Most important, we expect to complete enrollment in our pivotal trial of CORLUX for the treatment of Cushing’s Syndrome in the first quarter of this year. The results of this trial, if positive, should support an NDA submission by year-end and, if approved by the FDA, commercialization of CORLUX in 2011. We are focusing our efforts on preparing to make CORLUX commercially available to patients and address this significant unmet medical need.”


We expect to reach major milestones related to our development of CORLUX and our selective GR-II antagonists during 2010:

CORLUX for Cushing’s Syndrome

We are nearing completion of enrollment in our 50-patient open-label Phase 3 study of CORLUX for the treatment of endogenous Cushing’s Syndrome, a serious metabolic disorder affecting approximately 20,000 patients in the US.

Based on the timing of enrollment and the 6-month glucose tolerance and blood pressure endpoints agreed to with the FDA, we anticipate completing patient treatment in the Phase 3 trial of CORLUX for Cushing’s Syndrome and announcing efficacy results in 3Q 2010.

We expect to submit our NDA to the FDA in the fourth quarter of 2010. Additional studies and preparation of documentation in support of our NDA submission are ongoing, which should enable our submission soon after the Phase 3 efficacy results are available.

We are now preparing for the 2011 commercialization of CORLUX in the United States and pursuing partnerships for commercialization outside of the United States. Management is focused on making this potential treatment available to patients in an expeditious and efficient manner.

The FDA granted us Orphan Drug Designation for CORLUX for the treatment of endogenous Cushing’s Syndrome, which provides seven years of marketing exclusivity in the U.S. from the date of approval, as well as potential tax credits related to product development expenses.

Selective GR-II Antagonist — CORT 108297 — for the Prevention of Weight Gain Caused by Antipsychotic Medication

We plan to begin enrollment in the Phase 1 study of our lead selective GR-II antagonist, CORT 108297, in the first quarter of 2010, based on the Investigational New Drug (IND) application we submitted to the FDA in December 2009. The study is a single ascending dose safety and tolerability study in healthy volunteers, which should be completed by year-end 2010. If successful, this study should support advancing CORT 108297 into additional trials evaluating its safety and efficacy in the prevention of weight gain and other metabolic effects caused by antipsychotic medications, a major unmet medical need in a large market.

During 2010 we plan to continue our research and preclinical efforts to advance additional compounds within our three distinct series of selective GR-II antagonists. Based on the published literature, the regulation of cortisol could have applications in a wide array of serious diseases, including diabetes, obesity, hypertension, osteoporosis, Alzheimer’s disease, and other neurodegenerative diseases.

CORLUX for Psychotic Depression

We plan to continue enrolling patients in our Phase 3 trial of CORLUX for the treatment of psychotic depression. As previously announced, we are conducting the trial at eight clinical sites to focus our resources on completion of our NDA and the near-term commercialization of CORLUX for the Cushing’s Syndrome indication. With this reduced number of sites, we do not expect data from this trial to be available during 2010.

About Cushing’s Syndrome

Endogenous Cushing’s Syndrome is caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol due to a variety of pathologic conditions. Cushing’s Syndrome is an orphan indication which most commonly affects adults aged 20 to 50. An estimated 10 to 15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients in the US. An estimated 20,000 patients in the US have Cushing’s Syndrome. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are common. Cushing’s Syndrome can affect every organ system in the body and can be lethal if not treated effectively. There is no FDA-approved treatment for Cushing’s Syndrome.

About Psychotic Depression

Psychotic depression is a serious psychiatric disorder that affects approximately three million people annually in the United States. It is more prevalent than either schizophrenia or bipolar I disorder. The disorder is characterized by severe depression accompanied by delusions, hallucinations or both. People with psychotic depression are approximately 70 times more likely to commit suicide than the general population and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for psychotic depression.

About Weight Gain Caused by Antipsychotics

The group of medications known as atypical antipsychotics, including olanzapine, risperidone, clozapine and quetiapine, are widely used to treat schizophrenia and bipolar disorder. All medications in this group are associated with treatment emergent weight gain of varying degrees and carry warning labels relating to treatment emergent hyperglycemia and diabetes mellitus. Weight gain and alterations in metabolic efficiency have been observed for many years in patients with abnormally high circulating cortisol. There is no FDA-approved treatment for the weight gain associated with the use of antipsychotic medications.


Corcept’s first-generation compound, CORLUX, also known as mifepristone, directly blocks the GR-II (cortisol) receptor and the progesterone receptor. Intellectual property protection is in place to protect important methods of use for CORLUX. Corcept retains worldwide rights to its intellectual property related to CORLUX.

About CORT 108297

CORT 108297 is one of several potent, selective antagonists of the GR-II receptor that we have discovered and for which Corcept owns worldwide intellectual property rights. In in vitro binding affinity and functional assays it does not have affinity for the PR (progesterone), ER (estrogen), AR (androgen) or GR-I (mineralocorticoid) receptors.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. The company has two Phase 3 programs ongoing; CORLUX for the treatment of Cushing’s Syndrome and CORLUX for the treatment of the psychotic features of psychotic depression. Corcept has also developed an extensive intellectual property portfolio that covers the use of GR-II antagonists in the treatment of a wide variety of psychiatric and metabolic disorders, including the prevention of weight gain caused by the use of antipsychotic medication.

Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to Corcept’s clinical development and research programs, the timing of the introduction of CORLUX and future product candidates, including CORT 108297, estimates of the timing of enrollment or completion of our clinical trials and the anticipated results of those trials, the ability to create value from CORLUX or other future product candidates and our estimates regarding our capital requirements, spending plans and needs for additional financing. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances with respect to the cost, rate of spending, completion or success of clinical trials; financial projections may not be accurate; there can be no assurances that Corcept will pursue further activities with respect to the development of CORLUX, CORT 108297, or any of its other selective GR-II antagonists. These and other risk factors are set forth in the Company’s SEC filings, all of which are available from our website (www.corcept.com) or from the SEC’s website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.

Caroline Loewy
Chief Financial Officer
Corcept Therapeutics
Email Contact

From http://finance.yahoo.com/news/Corcept-Therapeutics-iw-1712742677.html?x=0&.v=1

What new treatments of tests have you tried?

%d bloggers like this: